Prohep: Innovative Microbial Therapy for Liver Health and Cancer Prevention
香港-海外项目平台 / 重点项目
香港-海外项目平台 / 重点项目
项目简介
Prohep is a groundbreaking microbial therapy designed for the **prevention and treatment of liver diseases**, including liver cancer, MASLD, and hyperlipidemia. Unlike conventional chemotherapy, targeted therapy, or immunotherapy—which face challenges such as high recurrence, short survival time, severe side effects, and high costs—Prohep offers a safer and more economical solution.
**Key Advantages:**
* **Prevents liver cancer recurrence** and effectively improves survival rates.
* **Reduces hyperlipidemia symptoms** while improving patient quality of life.
* **Patented technology**, ensuring exclusivity and strong market potential.
* Supported by **university-led scientific research** and clinical expertise.
**Market Potential:**
* Liver cancer remains a leading cause of death in China, with **367,700 new cases annually** and a **global treatment cost exceeding $40 billion**.
* Prohep’s dual positioning—first as a **supplement food** (ProheB+) and later as an **OTC drug**—maximizes both near-term revenue and long-term clinical adoption.
**Roadmap:**
* Commercial rollout of ProheB+ in Asia.
* Clinical studies and patent expansion.
* Angel round fundraising of **HKD 20M** to support research, trials, and global market entry.
**Vision:**
Prohep is positioned to transform liver disease prevention and treatment, bridging the gap between **scientific innovation and accessible healthcare**. With a scalable business model and strong team of global experts, it represents a unique investment opportunity in the **next generation of microbial therapies**.